HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy.

Publikation

HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy.

Wissenschaftlicher Artikel/Review - 14.02.2023

Zděblová Čermáková Zuzana, Hurník Pavel, Konvalinka David, Štembírek Jan, Paračková Tereza, Resová Kamila, Cvek Jakub, Blažek Tomáš, Knybel Lukáš, Formánek Martin, Gachechiladze Mariam, Jörger Markus, Soltermann Alex, Škarda Jozef, Motyka Oldřich, Janoutová Jana

Zitation

Zděblová Čermáková Z, Hurník P, Konvalinka D, Štembírek J, Paračková T, Resová K, Cvek J, Blažek T, Knybel L, Formánek M, Gachechiladze M, Jörger M, Soltermann A, Škarda J, Motyka O, Janoutová J. HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy. Medicina (Kaunas) 2023; 59

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Medicina (Kaunas) 2023; 59

Veröffentlichungsdatum

14.02.2023

eISSN (Online)

1648-9144

Kurzbeschreibung/Zielsetzung

The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway.